RA Capital Management Increases Stake in Acrivon Therapeutics to 28.8% via ATM Offering

On April 23, 2026, RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed an amendment to their Schedule 13D regarding Acrivon Therapeutics, Inc. (ACRV). The filing reports a significant increase in their position following the RA Capital Healthcare Fund's purchase of 3,888,888 shares of common stock on April 22, 2026. This transaction was conducted through an at-the-market (ATM) offering at a price of $1.80 per share, totaling approximately $7 million in consideration funded by the fund's working capital. Following this acquisition, the Reporting Persons collectively beneficially own 12,284,906 shares, representing 28.8% of the company's outstanding common stock. This is an increase from their previously reported 21.6% ownership (8,396,018 shares). The total holdings include 11,803,094 shares held by the Healthcare Fund, 426,302 shares held by RA Capital Nexus Fund II, L.P., and 55,510 vested stock options held for the benefit of RA Capital. RA Capital maintains sole voting and dispositive power over the shares via delegation from the respective funds.